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httpcense.Abstract The aim of this study was to retrospectively evaluate 47 patients (37 males and 10
females, aged 37–72 years) with life threatening hemoptysis treated by bronchial artery emboliza-
tion. Between April 2007 and April 2012 at the Assuit University Hospital, the cause of hemoptysis
was tuberculosis and post TB bronchiectasis in 29 patients, bronchiectasis in 11, 3 arteriovenous
malformation, 3 post infective ﬁbrosis and one patient with chronic renal failure. Recurrence of
hemoptysis after embolization occurred in 2 patients within the 6 month follow-up period, these
cases underwent re-embolization with successful control of hemoptysis. There were no proce-
dure-related major complications. Bronchial artery embolization is a safe and effective palliative
treatment for patients with massive hemoptysis.
ª 2013 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.069589065 (A. Rashad), +20
m (A. Rashad), aminchestmed
e Egyptian Society of Chest
g by Elsevier
ng by Elsevier B.V. on behalf of T
://dx.doi.org/10.1016/j.ejcdt.2013.0Introduction
Life threatening hemoptysis is one of the most challenging
conditions encountered in critical care and requires a thorough
and timely investigation.
Massive hemoptysis has been described as the expectora-
tion of an amount of blood ranging from 100 mL to more than
1000 mL over a period of 24 h, the most widely used criterion
is the production of 300–600 mL per day [1–4]. However,
depending on the ability of the patient to maintain a patent
airway, a life threatening condition may be caused by a rather
small amount of hemorrhage. Thus, a more functional deﬁni-he Egyptian Society of Chest Diseases and Tuberculosis.
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756 A. Rashad et al.tion of ‘‘massive’’ as an amount sufﬁcient to cause a life threat-
ening condition should be used in deciding whether to under-
take interventional management [4,5].
Massive hemoptysis may result from various causes, and
the frequency with which these causes occur differs greatly be-
tween the Western and the non-Western world. In the non-
Western world, pulmonary tuberculosis, including tuberculosis
bronchiectasis, is the most common underlying cause of mas-
sive hemoptysis. Bronchogenic carcinoma and chronic inﬂam-
matory lung diseases due to bronchiectasis, cystic ﬁbrosis, or
aspergillosis are the more prevalent causes of hemoptysis in
Western countries [1,2,4]. Other causes include lung abscess,
pneumonia, chronic bronchitis, pulmonary interstitial ﬁbrosis,
pneumoconiosis, pulmonary artery aneurysm (Rasmussen
aneurysm), congenital cardiac or pulmonary vascular anoma-
lies, aortobronchial ﬁstula, ruptured aortic aneurysm, and rup-
tured bronchial artery aneurysm [6].
Despite advances in medical and intensive care unit man-
agement, massive hemoptysis remains a serious threat.
According to recently published data, 28% of chest clinicians
had experienced patient death from massive hemoptysis during
a previous 1-year period [7]. Conservative management of
massive hemoptysis carries a mortality rate of 50–100% [1].
The cause of death is usually asphyxiation, not exsanguination
[2]. The reported mortality rates for surgery performed for
massive hemoptysis range from 7.1% to 18.2% [3]. However,
the mortality rate increases signiﬁcantly, up to about 40%,
when the surgery is undertaken as an emergency procedure [3].
Bronchial artery embolization (BAE) has become an estab-
lished procedure in the management of massive and recurrent
hemoptysis; its use was ﬁrst reported in 1973 by Remy et al. [8].
The efﬁcacy, safety, and utility of BAE in controlling massive
hemoptysis have been well documented in many subsequent re-
ports [9–17]. Because of poor pulmonary reserve and other
medical comorbid conditions, most patients with massive hem-
optysis are not surgical candidates [1,2]. However, surgery re-
mains the procedure of choice in the treatment of massive
hemoptysis caused by speciﬁc conditions, such as hydatid cyst,
thoracic vascular injury, bronchial adenoma, and aspergilloma
that is resistant to other therapies [4]. Even in surgical candi-
dates, BAE is effective in preparing the patient for elective
rather than high-risk emergency surgery [3].
Methods
During the period between April 2007 and April 2012, 47 pa-
tients with life threatening hemoptysis were treated by bron-
chial artery embolization at the Assuit University Hospital,
Assuit, Egypt.
Bronchoscopy ﬁndings were taken into consideration when-
ever they were available. We did not insist on this procedure in
order not to delay the treatment. Chest computed tomography
was done for those patients without localization of site of
bleeding by chest X-ray. Bilateral bronchial angiography was
performed in every case.
Angiography was performed via femoral access in all pa-
tients. A 5F vascular sheath was used in all cases to facilitate
catheter changes. 4F cobra or Simmons-1 catheters were used
for selective catheterization. A microcatheter was used when
necessary to ensure safe catheterization.Assessment included selective bronchial angiography in
every case. Additional angiography of the intercostal, subcla-
vian or inferior phrenic arteries was performed depending on
the location of the disease in the lung. Further ﬂush angiogra-
phy of the aortic arch and thoracic aorta was performed if the
source was not identiﬁed. Pulmonary angiography was not
routinely performed except in cases with suspected pulmonary
arteriovenous malformation.
Extravasation of contrast medium, thrombosis, hypertro-
phy or tortuosity of the vessels, pseudoaneurysms, parenchy-
mal staining and arteriovenous shunting were considered
positive angiographic ﬁndings.
After selective catheterization of the bleeding source in the
bronchial artery or non-bronchial systemic vessels, emboliza-
tion was performed under ﬂuoroscopic control using 250–
350 lm and 350–500 lm sized polyvinyl alcohol (PVA) parti-
cles (Contour; Boston Scientiﬁc, Natick, MA) suspended in
contrast medium. 350–500 lm PVA particles were used in pa-
tients with bronchopulmonary shunts and large bronchial
arteries. Embolization was terminated when antegrade ﬂow
was observed to stagnate or terminate.
Coils 5/10 mm and 3/4 mm sized (Cook, Bjaeverskov, Den-
mark) were used to embolize the bleeding source in cases with
large arteriovenous malformation. (Fig. 1, shows Large AVM
before and after embolization and coiling).
In patients with recurrent bleeding, additional bronchial ar-
tery, aberrant bronchial artery and abnormal non-bronchial
systemic and pulmonary supply were investigated with
angiography.
Results
The current study included 47 patients with recurrent massive
hemoptysis, uncontrolled by medical treatment, 37 (79%)
males and 10 (21%) females were included, age range from
37 to 72 years. 8 (17%) current smokers, 18 (38%) ex-smokers
and 21 (45%) non smokers were included (Table 1).
Most of patients had hemoptysis due to past pulmonary TB
lesions including ﬁbrosis, bronchiectasis and mycetoma (29 pa-
tients 62%), also 11(23%) patients with bronchiectasis were in-
cluded other 7 (15%) cases were 3 patients with arteriovenous
malformations, 3 cases with post infective ﬁbrosis and one case
with renal failure Fig. 2.
Total of 109 embolization were done ranging (1–5) per pa-
tient, including bronchial and non-bronchial systemic arteries.
Recurrence of hemoptysis occurred in 2 patients within the
6 month follow-up period, these cases underwent re-emboliza-
tion with successful control of hemoptysis. There were no ma-
jor procedure related complications.
Discussion
Severe hemoptysis occurs most commonly in patients with a
history of chronic inﬂammatory pulmonary disease. In the
non-Western world, pulmonary tuberculosis – including tuber-
culous bronchiectasis – is the most common underlying cause
in severe hemoptysis [18]. Despite the increase in human
immunodeﬁciency virus (HIV) associated tuberculosis in the
West, malignancy, cystic ﬁbrosis and other non-tuberculous
causes are still the most frequently reported causes [19]. In this
Table 1 Demographic data and smoking status no (%).
Age (mean ± SD) 41 ± 12
Sex
Male 37 (79%)
Female 10 (21%)
Smoking status
Current smoker 8 (17%)
Ex-smoker 18 (38%)
Non-smoker 21 (45%)
A B
Figure 1 Large arteriovenous malformation before (A) and after (B) embolization and coiling.
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tuberculosis was the etiology in 69% of cases [20].
CT has diagnostic superiority over bronchoscopy and chest
radiograph for demonstrating underlying pathology and the
site of bleeding in hemoptysis, especially in bronchiectasis,
bronchogenic carcinoma and aspergilloma cases [19]. Vascular
pathologies such as arteriovenous malformation or aneurysm,
which are rare causes of hemoptysis, are also depicted very
clearly in contrast enhanced CT examinations [12]. With recent
developments in multidetector CT technique it is now possible
to scan the whole thorax with very thin slices (1.25 mm) in a
very short time (12–15 s) [21,22]. Both the lesion causing hem-
optysis and the bronchial and non-bronchial systemic feedingFigure 2 Etiology of hemoarteries are detected during the same study using 80–100 mL
of contrast medium. In angiography controlled studies, 86–
87% of the pathologic vessels detected by angiography are
reportedly demonstrated with CT angiography (CTA) as well
[21,22]. The road map thus prepared for the interventional
radiologist by CTA is thought to shorten the examination time
in critical patients [23].
The source of severe hemoptysis is the bronchial circulation
in 90% of cases [24]. Signiﬁcant bleeding from the pulmonary
circulation is rare (5%) and is usually secondary to erosion of a
pulmonary arterial branch by chronic inﬂammation. It is rec-
ommended to investigate the pulmonary circulation for a
bleeding source following systemic arterial embolization, in pa-
tients with recurring hemoptysis due to ﬁbrocavitary tubercu-
losis [25]. In a minority of cases (approximately 5%) severe
hemoptysis may originate from the aorta (e.g., aortobronchial
ﬁstula, ruptured aortic aneurysm) or non-bronchial systemic
pulmonary arteries [26,27]. Intercostal arteries, thoracic arter-
ies originating from axillary and subclavian arteries in the
upper and inferior phrenic artery in the lower zone disease
should be investigated during the initial session, particularly
in cases with chronic infection and pleural disease because
non-bronchial systemic artery supply is the most important
cause of early recurrent hemoptysis after successful bronchial
artery embolization [25].ptysis in study patients.
758 A. Rashad et al.The recent emergence of BAE as a therapeutic modality for
life threatening massive hemoptysis has revolutionized man-
agement of the disease, as it is a less invasive but reliable pro-
cedure that leads to excellent therapeutic outcomes [28,29,7].
Nevertheless, surgical management of massive hemoptysis still
plays an important role as a therapeutic strategy.
Since the ﬁrst report by Remy and colleagues in 1973 [30],
the use of BAE for management of life threatening massive
hemoptysis has become widespread. Furthermore, develop-
ments and application of superselective BAE with a coaxial
microcatheter system [31], have accelerated that trend. Accord-
ing to recent outcomes reported by the Mayo Clinic group [32],
immediate control of bleeding was reached successfully in 94%
of the cases, with 30-day control obtained in 85% of the
remaining patients. Also, the Singaporean group [33], working
in a region where most hemoptysis cases are related to tuber-
culosis with pleural abnormalities that may require repeated
difﬁcult embolization [34], reported excellent outcomes in pa-
tients who underwent BAE, with an overall success rate of
81.6%.
Currently, PVA particles are the most commonly used
agents for bronchial artery embolization worldwide. PVA par-
ticles are biocompatible and non-biodegradable and are con-
sidered to be a permanent embolic agent. However,
unpredictable proximal vessel occlusion and catheter blockage
caused by clumping or aggregation of irregular-shaped PVA
particles have been reported [35]. Recently, the interest in
spherical agents has grown, to overcome the drawbacks of
PVA. Trisacryl gelatine microsphere (Embosphere; Biosphere,
Rockland, MA; Contour SE; Boston Scientiﬁc, Boston, MA)
is a new embolic agent that is increasingly used for uterine ﬁ-
broid embolization. In vivo and in vitro studies have shown
that these particles clearly have better sizing and penetration
characteristics than PVA [36]. Vinaya et al. reported a myocar-
dial infarction followed by stroke in a patient with hemoptysis
due to spontaneous passage of particles through the broncho-
pulmonary shunts with 500 lm sized embospheres [37]. It is
obvious that further clinical and experimental studies investi-
gating the effectiveness and safety of bronchial artery emboli-
zation with these particles are needed.
Acute control of hemoptysis with endovascular treatment
can be achieved in 73–98% of the patients with massive hem-
optysis [38–40]. However, hemoptysis can recur with a fre-
quency of up to 20%, especially in cases with chronic
tuberculosis, aspergilloma and neoplasia [41–43]. Recurrent
bleeding during the ﬁrst 6 months after the embolization pro-
cedure is usually due to undetected bronchial and systemic col-
laterals caused by diffuse pulmonary disease [25]. Late
recurrent bleeding (after 6 months) usually develops due to dis-
ease progression. In this study, hemoptysis recurred in 2 cases.
Armand et al., performed BAE in 28 patients with hemopt-
ysis, BAE was technically successful in all patients (bleeding
halted within 24 h). Recurrent bleeding occurred in four
patients with cystic ﬁbrosis (14%) [43].
Cornalba et al., retrospectively studied 534 patients with
hemoptysis who underwent BAE. Complete resolution of hem-
optysis was achieved within 24 h in 458/477 (96%) cases and
within 48 h in 2% of cases [44].
The successful results achieved with endovascular treatment
in the control of massive hemoptysis have also brought up the
idea of embolization of moderate and chronic recurrent, mild
hemoptysis compromising the life quality of the patient. Bar-ben et al. reported the results of bronchial artery embolization
in 46 bleeding episodes in 20 patients with cystic ﬁbrosis. There
were 22 massive, 10 moderate and 14 chronic recurrent bleed-
ing episodes [41]. They observed that immediate success was
achieved in 95% of the cases, whereas recurrent hemoptysis
occurred in 55% of the cases after a mean period of 4 months.
Yu-Tang et al. reported the success rate as 81.5% in their study
group consisting of 103 patients embolized for moderate to
massive hemoptysis [42]. They stressed that in 15.5% of cases
re-embolization would be necessary and that endovascular
treatment should be repeated whenever hemoptysis could be
controlled by this method. In this study, hemoptysis recurred
in 2 patients within a 6 month after embolization [20].
In summary, effective palliation with endovascular treat-
ment is achieved in the majority of moderate and massive hem-
optysis cases after a single intervention. If necessary, the
procedure may be repeated as long as the hemoptysis can still
be controlled by this method. Endovascular treatment per-
formed by an experienced staff with sufﬁcient technical back-
up is an effective and safe choice in the control of primary
and recurrent hemoptysis. We believe that bronchial artery
embolization should always be considered for treatment of
moderate to massive hemoptysis.
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